# Effectiveness of Eicosapentaenoic and Docosahexaenoic Acid Supplementation for Reducing Uremic Pruritus: A Meta-Analysis of Randomized Controlled Trials

**Authors:** Chia-An Chou, Lung-Chih Li, Wen-Chin Lee, Chiang-Chi Huang

PMC · DOI: 10.3390/ph19010181 · 2026-01-20

## TL;DR

This study finds that omega-3 fatty acids like EPA and DHA can reduce itching in patients with kidney failure.

## Contribution

A meta-analysis showing that EPA and DHA supplementation reduces uremic pruritus severity in end-stage renal disease patients.

## Key findings

- Omega-3 supplementation significantly reduced pruritus severity compared to placebo.
- Higher doses of EPA, DHA, and longer treatment duration were linked to better outcomes.
- No serious adverse events were reported with omega-3 supplementation.

## Abstract

Background: Uremic pruritus is a distressing and common symptom in patients with end-stage renal disease. The development of uremic pruritus involves a multifactorial pathogenesis, including systemic inflammation, dysregulated immune responses, and altered opioid receptor activity. Omega-3 polyunsaturated fatty acids have been reported to mitigate uremic pruritus symptoms. Among omega-3 fatty acids, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) have been reported as potential candidates for alleviating uremic pruritus due to their anti-inflammatory properties. Methods: A meta-analysis of seven randomized controlled trials was conducted to evaluate the efficacy of omega-3 supplementation in alleviating uremic pruritus among patients affected with end-stage renal disease. Effect sizes were calculated using Hedges’ g with a random-effects model. Heterogeneity, sensitivity, and meta-regression analyses were performed to explore influencing factors. Results: A total of 266 participants were included for analysis. Omega-3 supplementation significantly reduced pruritus severity compared with placebo. Sensitivity analyses were conducted to exclude a single large trial contributing to the results. Meta-regression indicated that higher EPA, DHA, and total omega-3 dosages, and longer treatment duration, were associated with reduced severity of the uremic pruritus than the placebo. No serious adverse events were reported. Conclusions: Omega-3 fatty acid supplementation significantly alleviates uremic pruritus in patients with ESRD. These findings support the use of omega-3 fatty acids as a safe and effective adjunct therapy. Further large-scale, long-term trials are warranted to verify these results and assess the long-term effects and safety of omega-3 fatty acids in attenuating uremic pruritus.

## Linked entities

- **Chemicals:** eicosapentaenoic acid (PubChem CID 5282847), docosahexaenoic acid (PubChem CID 445580)
- **Diseases:** end-stage renal disease (MONDO:0004375)

## Full-text entities

- **Diseases:** ESRD (MESH:D007676), inflammation (MESH:D007249), Uremic Pruritus (MESH:D011537)
- **Chemicals:** EPA (MESH:D015118), Eicosapentaenoic and Docosahexaenoic Acid (-), Omega-3 (MESH:D015525), DHA (MESH:D004281)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12844951/full.md

---
Source: https://tomesphere.com/paper/PMC12844951